Six top tips to prepare for the new EU Clinical Trial Regulation

The European Union Clinical Trial Regulation 536/2014 (EU-CTR) aims to standardize and harmonize the conduct and management of interventional clinical trials across the European Economic Area (EEA), with legally binding rules on requirements and increased transparency. The new EU-CTR promises a simplified process designed to decrease the burden resulting from idiosyncratic interpretations of the current EU-CTD. But to reap efficiencies, sponsors must sow operational changes. This article covers the six essential preparations companies should undertake now.

Open PDF

Return to Insights Center

Related Insights


Ensuring future success in a new market by delivering a robust safety database solution

Aug 4, 2023


Australia: The Regulatory and Reimbursement Environment

Aug 28, 2023


Lessons from China and the United States on the use of RWE in regulatory submissions

Jul 19, 2021


Expedited Pathways Comparisons - US EU CHN

Oct 19, 2021


Assessing the need for comparative clinical trials in biosimilar development programs

Sep 21, 2023


Highlights from ISMPP Asia Pacific Meeting 2021

Sep 20, 2021


New FDA Guidance Addresses the Need for Data-Generation Strategies Across the Drug Development Lifecycle

May 10, 2022


On-demand webinar: An expert guide to EU-CTR

Mar 10, 2022


New endpoints for early-stage cancer are gaining regulatory traction

Jan 28, 2022


Creating EU-CTR compliant and patient-friendly lay language summaries (LLS)

Jan 26, 2022


How emerging biotechs can enter the Chinese market and prosper

Jan 18, 2022


Studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial

Nov 19, 2021